NEWS & EVENTS

Therapeutic Opportunities for Dry Powder Inhalers Increasing

Greystone Associates Analyzes Technology and Therapeutic Factors Influencing Growth in Dry Powder Inhalers

(Amherst, NH) – The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative device designs for dry powder inhalers - is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, a new survey reveals the emerging developments and market dynamics that have positioned dry powder inhalers as the technology of choice for an increasing number of therapeutic drugs.

The survey concludes that the rising potential of dry powder inhalers is being driven by escalating research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. “The combination of improved particle properties and more efficient dry powder inhaler designs is creating new opportunities for dry powder inhalers and expanding the range of active compounds that can be effectively delivered via the lung”, explains George Perros, Greystone’s Managing Director. “We believe dry powder inhalation will become a major factor in the delivery of a number of emerging therapeutics.”

These findings are contained in a new and comprehensive report: Dry Powder Inhalation: Drugs, Devices, And Delivery Therapeutics. It includes comprehensive assessments of dry powder inhalation technology, profiles of dry powder inhalation market participants, industry data and forecasts, and detailed analysis of design and economic factors.

Source: Greystone Associates

 Dry Powder Inhalers Main Page